[{"orgOrder":0,"company":"Cipla","sponsor":"Wanbury Limited","pharmaFlowCategory":"D","amount":"$12.3 million","upfrontCash":"Undisclosed","newsHeadline":"Cipla acquires 4 key brands from Wanbury for up to Rs 89 crore.","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"February 2020","url1":"","url2":"","graph1":"Hematology","graph2":"Approved"},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cipla ready with repurposed HIV drug to combat coronavirus\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cipla Completes Phase-3 Clinical Study Of A Billion-Dollar Asthma Generic\n","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"April 2020","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Cipla","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gilead Inks Voluntary Licensing Agreements With Multiple Companies for Remdesivir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"May 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cipal's Clinical Trials Using Arthritis Drug Tocilizumab Get Nod","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"INDIA","productType":"Large molecule","productStatus":"Approved","date":"May 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Cipla","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Roche Pharma India Expands Partnership with Cipla to Improve Access to Key Oncology Medicines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Large molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cipla Launches Cipremi the only U.S. FDA Approved Emergency Use Authorisation (EUA) Treatment for Patients with Severe COVID-19 Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Cipla","sponsor":"Indian Institute of Chemical Technology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cipla Receives Regulatory Approval for Launch of Ciplenza (Favipiravir 200 mg) in India to Treat Mild to Moderate COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Cipla","sponsor":"Stempeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cipla and Stempeutics Collaborate for Launch of\nStempeucel\u00ae, First \u2018Made in India\u2019 Cell Therapy to\nTreat Critical Limb Ischemia (CLI)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Cell and Gene therapy","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cipla Receives Final Approval for Generic Version of Biogen IDEC Inc.'s Tecfidera\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cipla Launches Nintib to Treat Idiopathic Pulmonary Fibrosis, in Continuation of its Fight Against Rare Lung Diseases","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cipla Seeks Approval from CDSCO Panel to Modify Remdesivir Composition to Reduce Renal Toxicity","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Cipla","sponsor":"Alvotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cipla Gulf and Alvotech Expand Partnership for Commercialization of Biosimilars in Australia and New Zealand","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Large molecule","productStatus":"Biosimilar","date":"March 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cipla Receives Final Approvl for Generic Version of GlaxoSmithKline\u2019s IMITREX\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Cipla","sponsor":"SIGA Technologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cipla Therapeutics and SIGA Technologies Announce Strategic Partnership","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"INDIA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery"},{"orgOrder":0,"company":"Cipla","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Five Pharma Majors Collaborate for Clinical Trial of Oral Anti-Viral Drug Molnupiravir to Treat Mild Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cipla Receives Final Approval for Generic Version Of Sunovion Pharmaceuticals, Inc.'s Brovana\u00ae","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cipla Receives Final Approval for Generic Version of Novartis Pharmaceuticals Corporation Durezol\u00ae (Difluprednate Ophthalmic Emulsion 0.05%)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Cipla","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cipla to sell Eli Lilly's Insulin Products Humalog, Trulicity in India","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Peptide","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cipla Receives Final Approval for Lanreotide Injection","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Peptide","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cipla Receives Emergency Use Authorisation (EUA) to Launch Oral Anti-Viral Drug Cipmolnu\u00ae (Molnupiravir 200mg) in India for Treatment of Adult Patients With COVID-19, with SpO2>93% And with High Risk of Disease Progression Including Hospitalization or Dea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cipla and DNDi Launch Child-Friendly 4-in-1 Antiretroviral Treatment for Young Children Living with HIV in South Africa","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cipla Receives USFDA Approval for Generic Version of Revlimid\u00ae (Lenalidomide capsules)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cipla Announces Launch Of Leuprolide Acetate Injection Depot (22.5Mg)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Peptide","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Cipla","sponsor":"Ethris","pharmaFlowCategory":"D","amount":"$16.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cipla EU to Invest EUR 15 Million In Ethris, Initiating A Strategic Collaboration","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery","country":"INDIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery"},{"orgOrder":0,"company":"Cipla","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cipla Signs Agreement with Novartis for Diabetes Therapy Galvus Range","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CDSCO Panel Gives Nod for FDC Tamsulosin + Solifenacin","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Urology","graph2":"Approved"},{"orgOrder":0,"company":"Cipla","sponsor":"Actor Pharma","pharmaFlowCategory":"D","amount":"$48.6 million","upfrontCash":"$48.6 million","newsHeadline":"Cipla to Acquire South Africa-based Actor Pharma","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved"},{"orgOrder":0,"company":"Cipla","sponsor":"Luye Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Luye Pharma Grants Cipla Medpro Exclusive Distribution and Marketing Rights for Seroquel\u00ae and Seroquel XR\u00ae in South Africa and Certain Neighbouring Countries","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"February 2020","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"},{"orgOrder":0,"company":"Cipla","sponsor":"Pulmatrix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$22.0 million","newsHeadline":"Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement with Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Cipla
Under the amendment Cipla and Pulmatrix agreed to stop patient enrollment of the Ph2b study of PUR1900 (itraconazole) at 8 subjects and close the study. Cipla will take sole responsibility for development of PUR1900 in the treatment of Allergic Bronchopulmonary Aspergillosis.
Through the acquisition, Cipla strengthen its wellness portfolio by gaining access of Nozohaem (glycine and Calcium), a unique, gel treatment for nosebleeds that stops the bleeding in moments.
Under the terms of the agreement, Cipla will manufacture and market Galvus (vildagliptin) and Galvus combination brands, used in the treatment of type 2 diabetes.
ETH45 is a first-in-class inhalable form of Ethris’ proprietary mRNA for treatment of pulmonary alveolar proteinosis (PAP). ETH45 activates granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling in the presence of anti-GM-CF antibodies.
Solifenacin is a muscarinic receptor antagonist and tamsulosin is an alpha-1A and alpha-1B adrenergic receptor antagonist used to treat benign prostatic hyperplasia.
Leuprolide Acetate Injection Depot contains 22.5 mg of leuprolide acetate for 3- month administration given as a single dose injection. . It is supplied as lyophilized microspheres in a single dose vial as a kit with a prefilled syringe.
Lenalidomide is an immunomodulatory prescription drug which is indicated for several hematological malignancies in adults such as; Multiple Myeloma, Myelodysplastic syndromes, Mantle cell lymphoma, Follicular lymphoma, and Marginal Zone lymphoma.
The ‘4-in-1’ combination contains an antiretroviral combination of Abacavir, as an alternative first-line regimen for infants and young children with HIV – in the form of granule-filled capsules.
Cipmolnu® (Molnupiravir 200mg), first oral antiviral approved by the UK MHRA for the treatment of mild-to-moderate COVID-19 receives EUA by permission by the Drug Controller General of India.
Company received final approval for its Lanreotide acetate-Generic Injection, from USFDA for the treatment of patients with Acromegaly and Gastroenteropancreatic Neuroendocrine Tumors.